JFS Wealth Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

JFS Wealth Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4	Closed	–	–	1952
2021 Q4	$0	Buy	+4	New	+$35	﹤0.01%	1869

Other funds holding SGMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JFS Wealth Advisors's SGMO Position: Q1 2022 in Review

JFS Wealth Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2022, closing a stake of 4 shares.

JFS Wealth Advisors first reported a position in SGMO in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 195 funds tracked by Wall St. Rank hold SGMO as of Q1 2022.

JFS Wealth Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2022 after selling out during the quarter.
JFS Wealth Advisors sold 4 SANGAMO THERAPEUTICS INC shares in Q1 2022.
JFS Wealth Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q4 2021 and held it in 1 quarter.
JFS Wealth Advisors's SANGAMO THERAPEUTICS INC position peaked at $0 in Q4 2021.
195 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2022.

Based on JFS Wealth Advisors's 13F filing for Q1 2022, filed 2 May 2022.